Results 31 to 40 of about 24,972 (163)

Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long‐Term Open‐Label Study

open access: yesNeuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Background Refractory chronic migraine (rCM) is a highly disabling condition for which novel safe and effective treatments are needed. Safety and long‐term efficacy of paresthesia‐free high cervical 10 kHz spinal cord stimulation (SCS) were here prospectively evaluated for the treatment of rCM.
Adnan Al‐Kaisy   +7 more
wiley   +1 more source

Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains

open access: yesBMC Biology, 2009
Background Clostridium botulinum is a taxonomic designation for at least four diverse species that are defined by the expression of one (monovalent) or two (bivalent) of seven different C. botulinum neurotoxins (BoNTs, A-G).
Smith Leonard A   +8 more
doaj   +1 more source

Outcomes in the Management of Pediatric Retrograde Cricopharyngeal Dysfunction

open access: yesThe Laryngoscope, EarlyView.
ABSTRACT Objective To review the presentation and treatment outcomes of pediatric patients with retrograde cricopharyngeal dysfunction (RCPD). Methods A retrospective chart review was performed on pediatric patients diagnosed with retrograde cricopharyngeal dysfunction (RCPD) and treated with cricopharyngeal botulinum toxin injection (CPBTI).
Aidan P. Wright   +3 more
wiley   +1 more source

Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk. [PDF]

open access: yesPLoS ONE, 2010
Botulinum neurotoxin (BoNT), the causative agent of botulism, a serious neuroparylatic disease, is produced by the anaerobic bacterium Clostridium botulinum and consists of a family of seven serotypes (A-H).
Miles C Scotcher   +2 more
doaj   +1 more source

Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice

open access: yesНеврология, нейропсихиатрия, психосоматика, 2022
Currently, eight natural serotypes of botulinum neurotoxin (BNT-A-G, -X) are known. The mechanism of action of all BNT serotypes is presynaptic blockade of SNARE transport proteins (Soluble N-ethylmaleimide-sensitive factor [NSF] Attachment Protein ...
R. K. Shikhkerimov, E. V. Istomina
doaj   +1 more source

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience Program

open access: yesMovement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective To report findings from PrevU, an early experience, real‐world observational
Laxman Bahroo   +10 more
wiley   +1 more source

The role of the host—Neutrophil biology

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple   +4 more
wiley   +1 more source

Botulinum Toxin Type B vs Type A in Cervical Dystonia: A Meta - analysis of high quality trials

open access: yesActa Neurológica Colombiana, 2012
Introduction: cervical dystonia (CD) is a frequent disabling condition. Botulinum Toxin (BT) type A is effective for CD. BT type B is an alternative, but its use for patients who develop neutralizing antibodies against BT type A is debatable ...
Diana M. Prada G
doaj   +2 more sources

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA

open access: yesToxins, 2020
Botulinum toxin type B (BoNT/B) has been recommended as an alternative for patients who have become resistant to botulinum toxin type A (BoNT/A). This study aimed to compare the clinical effect, within a patient, of four injections with low doses of ...
Harald Hefter   +2 more
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

open access: yesMovement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel   +48 more
wiley   +1 more source

Home - About - Disclaimer - Privacy